Programs & Pipeline
Fabry Disease Clinical Trials
Note to healthcare providers and patients: Amicus Therapeutics will provide support to patients and healthcare providers to help provide continued access to treatment. For more information, contact EarlyAccess@amicusrx.com.
A Thank You to All Participants: At Amicus, we believe that all study participants are equal clinical research partners in the drug development process. Without the support of their families, friends, and healthcare teams, the Amicus clinical research program could not move forward. Amicus would like to express its gratitude to the Fabry community and all involved in the ongoing and completed clinical trials and all of our clinical research.
MIGALASTAT MONOTHERAPY: PHASE 3 RENAL IMPAIRMENT SAFETY AND PHARMACOKINETIC STUDY (AT1001-025)
More information: www.clinicaltrials.gov: NCT04020055
Migalastat Monotherapy: Phase 3 Long-Term Safety Study 042 (AT1001-042 Study)
More information: www.clinicaltrials.gov: NCT02194985
Migalastat Monotherapy: Expanded Access Physician Initiated Request (MGM116188)
More information: www.clinicaltrials.gov: NCT01476163
MIGALASTAT MONOTHERAPY: CURRENTLY ENROLLING STUDY 020 (AT1001-020 STUDY)
More information: www.clinicaltrials.gov: NCT03500094